TARA PROTARA THERAPEUTICS INC US FDA Inspections 8-K Filing 2023 - FDA Clearance for Phase 2 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations Protara Therapeutics, Inc. received regulatory clearance from the FDA to commence Phase 2 STARBORN-1 trial of TARA-002 in pediatric patients with lymphatic malformations.Get access to all SEC 8-K filings of the PROTARA THERAPEUTICS INC